Prediction of drug clearance and drug-drug interactions in microscale cultures of human hepatocytes

Drug Metabolism and Disposition

Volumn 44, Issue 1, 2016, Pages 127-136

  Lin, Christine ^a,b   Shi, Julianne ^c   Moore, Amanda ^c   Khetani, Salman R ^a,b  

^a Department of Mechanical Engineering   (United States)

^b University of Illinois at Chicago   (United States)

^c Hepregen Corporation   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CYTOCHROME P450 1A2; CYTOCHROME P450 2A6; CYTOCHROME P450 2B6; CYTOCHROME P450 2C19; CYTOCHROME P450 2C8; CYTOCHROME P450 2C9; CYTOCHROME P450 2D6; CYTOCHROME P450 2E1; CYTOCHROME P450 3A4; DESIPRAMINE; DEXTROMETHORPHAN; DIAZEPAM; LORAZEPAM; METHYLPREDNISOLONE; MIDAZOLAM; PREDNISOLONE; RIFAMPICIN; SUMATRIPTAN; ZOLMITRIPTAN; CYTOCHROME P450; CYTOCHROME P450 INDUCER; CYTOCHROME P450 INHIBITOR; ISOENZYME;

ARTICLE; CONTROLLED STUDY; DRUG CLEARANCE; DRUG HALF LIFE; ENZYME ACTIVITY; HUMAN; HUMAN CELL; LIVER CELL; PREDICTION; PRIORITY JOURNAL; TURNOVER TIME; ADULT; BIOLOGICAL MODEL; CELL CULTURE; CELL CULTURE TECHNIQUE; COMPARATIVE STUDY; DRUG EFFECTS; DRUG INTERACTION; ENZYME SPECIFICITY; ENZYMOLOGY; FEMALE; KINETICS; MALE; METABOLIC CLEARANCE RATE; METABOLISM; MIDDLE AGED; RISK ASSESSMENT; YOUNG ADULT;

ADULT; CELL CULTURE TECHNIQUES; CELLS, CULTURED; CYTOCHROME P-450 ENZYME INDUCERS; CYTOCHROME P-450 ENZYME INHIBITORS; CYTOCHROME P-450 ENZYME SYSTEM; DRUG INTERACTIONS; FEMALE; HEPATOCYTES; HUMANS; ISOENZYMES; KINETICS; MALE; METABOLIC CLEARANCE RATE; MIDDLE AGED; MODELS, BIOLOGICAL; RISK ASSESSMENT; SUBSTRATE SPECIFICITY; YOUNG ADULT;

EID: 84958160549     PISSN: 00909556     EISSN: 1521009X     Source Type: Journal    
DOI: 10.1124/dmd.115.066027     Document Type: Article

References (35)

1. Atkinson AJ, Jr and Kushner W (1979) Clinical pharmacokinetics. Annu Rev Pharmacol Toxicol 19:105-127.
2. Berger DR, Ware BR, Davidson MD, Allsup SR, and Khetani SR (2014) Enhancing the functional maturity of induced pluripotent stem cell-derived human hepatocytes by controlled presentation of cell-cell interactions in vitro. Hepatology 61:1370-1381.
3. Bi Y-A, Kazolias D, and Duignan DB (2006) Use of cryopreserved human hepatocytes in sandwich culture to measure hepatobiliary transport. Drug Metab Dispos 34:1658-1665.
4. Blanchard N, Alexandre E, Abadie C, Lavé T, Heyd B, Mantion G, Jaeck D, Richert L, and Coassolo P (2005) Comparison of clearance predictions using primary cultures and suspensions of human hepatocytes. Xenobiotica 35:1-15.
5. Brown HS, Griffin M, and Houston JB (2007) Evaluation of cryopreserved human hepatocytes as an alternative in vitro system to microsomes for the prediction of metabolic clearance. Drug Metab Dispos 35:293-301.
6. Brunton L, Chabner B, and Knollman B (2011) Goodman and Gilman's The Pharmacological Basis of Therapeutics, 12th ed., McGraw-Hill Professional, New York.
7. Chan TS, Yu H, Moore A, Khetani SR, and Tweedie D (2013) Meeting the challenge of predicting hepatic clearance of compounds slowly metabolized by cytochrome P450 using a novel hepatocyte model, HepatoPac. Drug Metab Dispos 41:2024-2032.
8. Chao P, Barminko J, Novik E, Han Y, Maguire T, Cheng KC, Han Y, Maguire T, and Maguire T, et al. (2009) Prediction of human hepatic clearance using an in vitro plated hepatocyte clearance model. Drug Metab Lett 3:296-307.
9. Dash A, Inman W, Hoffmaster K, Sevidal S, Kelly J, Obach RS, Griffith LG, and Tannenbaum SR (2009) Liver tissue engineering in the evaluation of drug safety. Expert Opin Drug Metab Toxicol 5:1159-1174.
10. Di L and Obach RS (2015) Addressing the challenges of low clearance in drug research. AAPS J 17:352-357.
11. Di L, Trapa P, Obach RS, Atkinson K, Bi YA, Wolford AC, Tan B, McDonald TS, Lai Y, and Tremaine LM (2012) A novel relay method for determining low-clearance values. Drug Metab Dispos 40:1860-1865.
12. Godoy P, Hewitt NJ, Albrecht U, Andersen ME, Ansari N, Bhattacharya S, Bode JG, Bolleyn J, Borner C, and Böttger J, et al. (2013) Recent advances in 2D and 3D in vitro systems using primary hepatocytes, alternative hepatocyte sources and non-parenchymal liver cells and their use in investigating mechanisms of hepatotoxicity, cell signaling and ADME. Arch Toxicol 87: 1315-1530.
13. Gorski JC, Vannaprasaht S, Hamman MA, Ambrosius WT, Bruce MA, Haehner-Daniels B, and Hall SD (2003) The effect of age, sex, and rifampin administration on intestinal and hepatic cytochrome P450 3A activity. Clin Pharmacol Ther 74:275-287.
14. Hallifax D, Foster JA, and Houston JB (2010) Prediction of human metabolic clearance from in vitro systems: retrospective analysis and prospective view. Pharm Res 27:2150-2161.
15. Hariparsad N, Nallani SC, Sane RS, Buckley DJ, Buckley AR, and Desai PB (2004) Induction of CYP3A4 by efavirenz in primary human hepatocytes: comparison with rifampin and phenobarbital. J Clin Pharmacol 44:1273-1281.
16. Khetani SR and Bhatia SN (2008) Microscale culture of human liver cells for drug development. Nat Biotechnol 26:120-126.
17. Khetani SR, Kanchagar C, Ukairo O, Krzyzewski S, Moore A, Shi J, Aoyama S, Aleo M, and Will Y (2013) Use of micropatterned cocultures to detect compounds that cause druginduced liver injury in humans. Toxicol Sci 132:107-117.
18. Khetani SR, Berger DR, Ballinger KR, Davidson MD, Lin C, and Ware BR (2015) Microengineered liver tissues for drug testing. J Lab Autom 20:216-250.
19. Koepsell H, Lips K, and Volk C (2007) Polyspecific organic cation transporters: structure, function, physiological roles, and biopharmaceutical implications. Pharm Res 24:1227-1251.
20. Lau YY, Sapidou E, Cui X, White RE, and Cheng KC (2002) Development of a novel in vitro model to predict hepatic clearance using fresh, cryopreserved, and sandwich-cultured hepatocytes. Drug Metab Dispos 30:1446-1454.
21. Lecluyse EL (2001) Human hepatocyte culture systems for the in vitro evaluation of cytochrome P450 expression and regulation. Eur J Pharm Sci 13:343-368.
22. McGinnity DF, Soars MG, Urbanowicz RA, and Riley RJ (2004) Evaluation of fresh and cryopreserved hepatocytes as in vitro drug metabolism tools for the prediction of metabolic clearance. Drug Metab Dispos 32:1247-1253.
23. Nguyen TV, Ukairo O, Khetani SR, McVay M, Kanchagar C, Seghezzi W, Ayanoglu G, Irrechukwu O, and Evers R (2015) Establishment of a hepatocyte-kupffer cell coculture model for assessment of proinflammatory cytokine effects on metabolizing enzymes and drug transporters. Drug Metab Dispos 43:774-785.
24. Obach RS (1999) Prediction of human clearance of twenty-nine drugs from hepatic microsomal intrinsic clearance data: An examination of in vitro half-life approach and nonspecific binding to microsomes. Drug Metab Dispos 27:1350-1359.
25. Obach RS, Baxter JG, Liston TE, Silber BM, Jones BC, MacIntyre F, Rance DJ, and Wastall P (1997) The prediction of human pharmacokinetic parameters from preclinical and in vitro metabolism data. J Pharmacol Exp Ther 283:46-58.
26. Obach RS, Lombardo F, and Waters NJ (2008) Trend analysis of a database of intravenous pharmacokinetic parameters in humans for 670 drug compounds. Drug Metab Dispos 36: 1385-1405.
27. Rae JM, Johnson MD, Lippman ME, and Flockhart DA (2001) Rifampin is a selective, pleiotropic inducer of drug metabolism genes in human hepatocytes: studies with cDNA and oligonucleotide expression arrays. J Pharmacol Exp Ther 299:849-857.
28. Ramsden D, Tweedie DJ, Chan TS, and Tracy TS (2014) Altered CYP2C9 activity following modulation of CYP3A4 levels in human hepatocytes: an example of protein-protein interactions. Drug Metab Dispos 42:1940-1946.
29. Ring BJ, Chien JY, Adkison KK, Jones HM, Rowland M, Jones RD, Yates JWT, Ku MS, Gibson CR, and He H, et al. (2011) PhRMA CPCDC initiative on predictive models of human pharmacokinetics, part 3: comparative assessement of prediction methods of human clearance. J Pharm Sci 100:4090-4110.
30. Shih H, Pickwell GV, Guenette DK, Bilir B, and Quattrochi LC (1999) Species differences in hepatocyte induction of CYP1A1 and CYP1A2 by omeprazole. Hum Exp Toxicol 18:95-105.
31. Smith CM, Nolan CK, Edwards MA, Hatfield JB, Stewart TW, Ferguson SS, Lecluyse EL, and Sahi J (2012) A comprehensive evaluation of metabolic activity and intrinsic clearance in suspensions and monolayer cultures of cryopreserved primary human hepatocytes. J Pharm Sci 101:3989-4002.
32. Wang WW, Khetani SR, Krzyzewski S, Duignan DB, and Obach RS (2010) Assessment of a micropatterned hepatocyte coculture system to generate major human excretory and circulating drug metabolites. Drug Metab Dispos 38:1900-1905.
33. Wienkers LC and Heath TG (2005) Predicting in vivo drug interactions from in vitro drug discovery data. Nat Rev Drug Discov 4:825-833.
34. Wilkening S, Stahl F, and Bader A (2003) Comparison of primary human hepatocytes and hepatoma cell line Hepg2 with regard to their biotransformation properties. Drug Metab Dispos 31:1035-1042.
35. Williamson B, Dooley KE, Zhang Y, Back DJ, and Owen A (2013) Induction of influx and efflux transporters and cytochrome P450 3A4 in primary human hepatocytes by rifampin, rifabutin, and rifapentine. Antimicrob Agents Chemother 57:6366-6369.